SCHEMBL29699470

SCHEMBL29699470

Clc1ccc(Nc2c[nH]nn2)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 2/20 0.47
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
KMO O15229 1/20 0.43
RAPGEF4 Q8WZA2 1/20 0.41
GUSB P08236 2/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
KDR P35968 1/20 0.39
GRM4 Q14833 1/20 0.38
EPHX1 P07099 1/20 0.38
EPHX2 P34913 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
BRAF P15056 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15831508 0.85 RAPGEF4 (0.45) POLA1MEN1KMT2AMAPTRAPGEF4
SCHEMBL23457623 0.79 SCN9A (0.38) MAPTKDRNPC1RAB9AIDO1
SCHEMBL29699617 0.79 SCN9A (0.38) MAPTKDRNPC1RAB9AIDO1
SCHEMBL29699342 0.77 MAPT (0.41) MEN1KMT2AMAPTRAPGEF4GRM4
SCHEMBL23457510 0.76 MAPT (0.47) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL29699563 0.76 DHFR (0.41) MAPTRAPGEF4GRM4
SCHEMBL29699530 0.75 RAPGEF4 (0.42) MEN1KMT2ARAPGEF4HDAC3HDAC1
SCHEMBL15831504 0.74 MAPT (0.43) MEN1KMT2AMAPTRAPGEF4KDR
SCHEMBL23457500 0.73 MEN1 (0.37) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL29699515 0.73 MEN1 (0.37) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT POLA1 1115/4885MEN1 2988/4885KMT2A 4011/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT POLA1 1120/4885MEN1 2927/4885KMT2A 3699/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT POLA1 1115/4885MEN1 2988/4885KMT2A 4011/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT POLA1 1115/4885MEN1 2988/4885KMT2A 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.